Buying These 3 Stocks Is Like Making a Bet in a Burning House
George Budwell, The Motley Fool - Motley Fool - Mon Dec 22, 7:54AM CST
Source: Flickr user Mark Esau Bargain hunters are often attracted to beaten-down biotech stocks because they sometimes rebound in astonishing fashion. That said, it can be extremely difficult to separate the wheat from the chaff when mulling over...
OREX: 5.98 (+0.01), AZN: 70.44 (+0.26), VVUS: 2.99 (-0.02), AMGN: 160.67 (+3.15), AEGR: 21.59 (-0.27), SNY: 46.35 (+0.50), MNKD: 5.68 (+0.18)
Why Is George Soros Buying This Beaten Down Biotech Stock?
George Budwell, The Motley Fool - Motley Fool - Sun Dec 21, 10:04AM CST
Source: Wikimedia Commons/ Niccolò Caranti The controversial billionaire and hedge fund guru George Soros is undoubtedly one of the best investors on the planet today. At age 83, he is estimated to be the seventh-richest American, with a net...
PFE: 31.42 (-0.03), AZN: 70.44 (+0.26), SRPT: 13.88 (+0.47), AMGN: 160.67 (+3.15), AEGR: 21.59 (-0.27), SNY: 46.35 (+0.50)
Nominees for Absolute Worst Bio-Technology CEOs of 2014 Are ...
at The Street - Mon Dec 15, 10:49AM CST
The CEOs of Aegerion, Dendron, CytRx, Galena, Repros, Northwest Bio and Retrophin deserve jeers for their performances this year, but who's the worst of the bunch?
NWBO: 5.58 (+0.04), DNDN: 0.13 (-0.02), RTRX: 12.92 (+0.19), CYTR: 2.58 (+0.03), RPRX: 8.88 (+0.24), GALE: 1.49 (-0.02), AEGR: 21.59 (-0.27)
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program
GlobeNewswire - Mon Dec 08, 7:35AM CST
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that on December 1, 2014, Aegerion granted stock options to purchase an aggregate of 36,350 shares of common stock to 12 new employees under the inducement stock option program described below. Each stock option has an exercise price per share equal to $20.90, the closing price of Aegerion's common stock on the grant date; vests 25% on the first anniversary of the date of grant with the remaining 75% to vest in monthly installments over the three years thereafter; has a ten year term; and is subject to the terms and conditions of Aegerion's Inducement Award Stock Option Plan, and the terms and conditions of a stock option agreement covering the grant.
AEGR: 21.59 (-0.27)
Aegerion's Current Valuations Demand Attention
Value Insight - at Seeking Alpha - Sat Dec 06, 10:01AM CST
AEGR: 21.59 (-0.27), SNY: 46.35 (+0.50)
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Aegerion Pharmaceuticals, Inc.
PR Newswire - Mon Dec 01, 12:29PM CST
Levi & Korsinsky, LLP is investigating Aegerion Pharmaceuticals, Inc. (NasdaqGS: AEGR) in connection with possible breaches of fiduciary duty by the Board of Directors of the Company.
AEGR: 21.59 (-0.27)
Global PCSK9 and Other Novel Hypercholesterolemia Drugs Market: 10 Year Forecasts
M2 - Tue Nov 25, 5:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/3nhdt3/pcsk9_and_other) has announced the addition of the "PCSK9 and Other Novel Hypercholesterolemia Drugs" report to their offering. The PCSK9 and Other Novel Hypercholesterolemia Drugs, 2014 - 2024' report provides an extensive study of the new class of prescription drugs being evaluated for the treatment of high cholesterol levels caused both by genetic and lifestyle factors. The possibility of a drug to become blockbuster depends on various factors. In addition to safety and efficacy, other factors include cost, mode of administration, side effects and their approval and availability in various geographies. For each of these new classes of drugs, we have highlighted the key drivers and limiting factors. We have also presented our own perspective on how the acceptance and evolution of these drugs is likely to advance in the coming years. The analysis is backed by an extensive review of the hypercholesterolemia / dyslipidemia landscape and familial hypercholesterolemia (HoFH and HeFH) markets. The base year for the report is 2013. The report provides market forecasts for the following two time horizons: 2014 - 2019 (short-midterm) and 2019 - 2024 (long term), respectively. The figures mentioned in this report are in USD, unless otherwise specified. Key Highlights: - With statins going off-patent, pharmaceutical companies are hunting for next blockbusters for hypercholesterolemia. The approval and launch of Kynamro (ISIS Pharmaceuticals / Genzyme) and Juxtapid (Aegerion Pharmaceuticals) in late 2012 / early 2013 has changed the treatment paradigm for homozygous familial hypercholesterolemia. - The market for developing novel cholesterol lowering drugs has gained attention of a number of multinational pharmaceutical companies including Amgen, Sanofi, Pfizer, GSK, Eli Lilly, Roche, Johnson & Johnson and more. Overall, there are 27 companies developing 29 molecules in clinical trials. - Evolocumab, being developed by Amgen, has been filed with the FDA and EMA for approval. Four more drugs are being evaluated in Phase III clinical trials. Three of these five late stage drugs are PCSK9 inhibitors (monoclonal antibodies), all of which are being developed by large multinational pharmaceutical companies. - All three late stage PCSK9 inhibitors are monoclonal antibodies. Other approaches being investigated by drug developers include the use of antisense / siRNA and synthetic molecules. - 2015 is likely to witness parallel launch of two anti-PCSK9 mAbs. We expect Evolocumab and Alirocumab to be made commercially available during 2015, while Bococizumab is expected to be available by 2017. - Anacetrapib, an oral CETP inhibitor from Merck, can give head to head competition to PCSK9 inhibitors in dyslipidemia / hypercholesterolemia market if the Phase III outcome trial REVEAL shows positive results. - In the base scenario, we forecast the market to hit USD 10 billion sales by 2020. The upside is likely to be higher as the same drugs also start getting evaluated for treatment in the non-US and non-EU5 regions. Key Topics Covered: 1. Preface 2. Executive Summary 3. Hypercholesterolemia: A Major Problem 4. Current Market Landscape 5. Novel Marketed Drugs: Mttp Inhibitors And Apo B Gene Silencer 6. Pcsk9 Inhibitors: Key Molecules And Future Outlook 7. Cetp Inhibitors: Key Molecules And Future Outlook 8. Overall Market Outlook 9. Conclusion 10. Appendix 1: Tabulated Data 11. Appendix 2: List Of Companies For more information visit http://www.researchandmarkets.com/research/3n..._and_other
ISIS: 59.49 (+1.88), MRK: 57.46 (+0.25), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), AEGR: 21.59 (-0.27)
Critical Alerts For Cliffs Natural Resources, Ford, Delta Airlines, Halliburton and Aegerion Pharmaceuticals Released By InvestorsObserver
PR Newswire - Mon Nov 24, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for CLF, F, DAL, HAL and AEGR.
F: 15.30 (-0.03), DAL: 48.05 (+0.92), HAL: 39.70 (-0.18), AEGR: 21.59 (-0.27), CLF: 6.06 (-0.09)
Aegerion Pharmaceuticals to Present at the Deutsche Bank BioFEST Conference
GlobeNewswire - Fri Nov 21, 7:30AM CST
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced today that the company will participate in the Deutsche Bank BioFEST Conference in Boston. Marc Beer, chief executive officer of Aegerion, is scheduled to present on Tuesday, December 2, 2014 at 2:50 p.m. ET.
DB: 30.95 (+0.04), AEGR: 21.59 (-0.27)
Hynes Keller & Hernandez, LLC Announces Investigations of M/A-Com Technology Solutions Holdings, Inc., Stericycle, Inc. and Aegerion Pharmaceuticals, Inc.
PR Newswire - Thu Nov 13, 7:23AM CST
Hynes Keller & Hernandez, LLC is investigating potential claims against M/A-Com Technology Solutions, Stericycle, Inc. and Aegerion Pharmaceuticals, Inc. as detailed below.
MTSI: 32.39 (+0.57), SRCL: 133.27 (-0.16), AEGR: 21.59 (-0.27)
Aegerion Pharmaceuticals awards 35,000 common stock options under NASDAQ Listing Rules
M2 - Thu Nov 13, 6:57AM CST
Biopharmaceutical company Aegerion Pharmaceutical (NasdaqGS:AEGR) on Wednesday announced stock options to purchase an aggregate of 35,000 shares of its common stock to nine new employees entering into employment.
AEGR: 21.59 (-0.27)
Aegerion to Acquire Myalept, Boost Portfolio - Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 11:52AM CST
Aegerion Pharmaceuticals, Inc. (AEGR) has signed an agreement with AstraZeneca to acquire the latter's Myalept for $325 million.
BIIB: 340.89 (+5.13), AZN: 70.44 (+0.26), LLY: 70.16 (+0.42), AEGR: 21.59 (-0.27), GSK: 42.85 (+0.11)
AstraZeneca (AZN) Misses on Q3 Earnings, Raises Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 2:20PM CST
AstraZeneca (AZN) reported third-quarter 2014 core earnings of $1.05 per ADS that missed the Zacks Consensus Estimate by a penny.
AGN: 210.12 (+0.95), AZN: 70.44 (+0.26), ABBV: 66.21 (+1.86), AEGR: 21.59 (-0.27)
Why Aegerion Pharmaceuticals, Inc. Stock Collapsed in October
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 06, 7:36AM CST
AEGR data by YCharts What: Shares of Aegerion Pharmaceuticals , a biopharmaceutical company focused on developing drugs to treat rare diseases, collapsed in October and lost 40% of their value, based on data from S&P Capital IQ , after...
AMGN: 160.67 (+3.15), AEGR: 21.59 (-0.27)
AstraZeneca divests leptin deficiency med
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 7:31AM CST
AZN: 70.44 (+0.26), AEGR: 21.59 (-0.27)
Aegerion Buys Rare Disease Therapy, Seeking Path Out of Current Troubles
at The Street - Thu Nov 06, 6:55AM CST
Aegerion Pharmaceuticals is spending $325 million, or almost all of its cash, to purchase a recently approved, orphan-disease drug from AstraZeneca.
AZN: 70.44 (+0.26), AEGR: 21.59 (-0.27)
Aegerion Pharmaceuticals Acquires Myalept(TM) From AstraZeneca
GlobeNewswire - Thu Nov 06, 1:11AM CST
Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) today announced that it has entered into a definitive agreement with AstraZeneca to acquire Myalept(TM) (metreleptin for injection), an orphan product that is indicated to treat complications of leptin deficiency in patients with generalized lipodystrophy.
AEGR: 21.59 (-0.27)
Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 8:46AM CST
It was another earnings-focused week with several biotech companies yet to report third quarter results.
VRTX: 115.15 (+1.40), GERN: 3.06 (+0.05), AMGN: 160.67 (+3.15), ABBV: 66.21 (+1.86), AEGR: 21.59 (-0.27), SNY: 46.35 (+0.50), REGN: 400.12 (+6.07)
Quarterly Financial Results and Upcoming Conference - Research Reports on Mylan, Aegerion, Bard, Incyte and Boston Scientific
PR Newswire - Wed Nov 05, 7:50AM CST
Today, Analysts Review released its research reports regarding Mylan Inc. (NASDAQ: MYL), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), C.R. Bard, Inc. (NYSE: BCR), Incyte Corporation (NASDAQ: INCY) and Boston Scientific Corporation (NYSE: BSX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7704-100free.
BSX: 13.13 (+0.07), BCR: 169.10 (-0.44), INCY: 71.57 (+1.99), MYL: 56.97 (+0.39), AEGR: 21.59 (-0.27)